Low Rates of Sustained Virologic Response with Peginterferon Plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV Infected Patients in Rio de Janeiro, Brazil

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Barcaui, Halime Silva ^a   Tavares, Gerson Carreiro ^a   May, Silvia Beatriz ^a   Brandão Mello, Carlos Eduardo ^b   Amendola Pires, Márcia Maria ^b   Barroso, Paulo Feijó ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ERYTHROPOIETIN; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAZIL; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PUBLIC HEALTH; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; BRAZIL; CD4 LYMPHOCYTE COUNT; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 84879973516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067734     Document Type: Article

References (41)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N, (2010) Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin infec Dis. 34(6): 831-7.
2. Soriano V, Garcia Samaniego J, Valencia E, Rodríguez-Rosado R, Muñoz F, et al. (1999) Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur. J. Epidemiology. 15: 1-4.
3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis. 33: 562-569.
4. Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, et al. (2001) Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr. 26: 466.
5. Ragni MV, Belle SH, (2001) Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis c virus infection. J Infect Dis (183):: 1112-1115.
6. Soto B, Sánchez-Quijano A, Rodrigo L, del Olmo JA, García-Bengoechea M, et al. (1997) Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 26: 1-5.
7. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 32: 492-497.
8. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, et al. (2001) Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis (33):: 240-247.
9. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, et al. (2006) Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus: The D:A:D Study. Arch Intern Med166 (15):: 1632-1641.
10. Torriani FJ, Rockstroh JK, Rodriguez-Torres M, Lissen E, Gonzalez-García J, et al. (2004) Peginterferon-alfa-2a+ribavirin vs interferon-alfa-2a+ribavirin in the treatment of HCV in HIV/HCV co-infection. N Engl J Med. 351: 438.
11. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, et al. (2004) PEG-interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med. 351: 451.
12. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, et al. (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 292: 2839.
13. Bedossa P, Poynard T, (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology. 24: 289-293.
14. Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, et al. (2008) Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 22(1): 15-21.
15. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. (2011) Departamento de DST, AIDS e Hepatites virais. Protocolo clínico e diretrizes terapêuticas para hepatite viral C e coinfecções. Série A. Normas e Manuais Técnicos. Brasília (DF): Ministério da Saúde. Available: http://portal.saude.gov.br/portal/arquivos/pdf/prot_clinico_diretrizes_tera_hepatite_c.pdf. Accessed 12 november 2012.
16. Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, et al. (2011) Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr. 58(3): 261-8.
17. Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, et al. (2007) Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 23(8): 972-82.
18. Alavian SM, Tabatabaei SV, Behnava B, (2012) Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis. J Viral Hepat. 19(2): 88-93.
19. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, et al. (2004) Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 126(5): 1302-11.
20. Yu JW, Sun LJ, Kang P, Yan BZ, Zhao YH, (2012) Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 11(2): 185-92.
21. Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, et al. (2003) Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 98: 2491.
22. Sulkowski MS, Dieterich DT, Bini EJ, Bräu N, Alvarez D, et al. (2005) Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr. 39: 504.
23. Sharvadze L, Karchava M, Bolokadze N, Gatserelia L, Tsertsvadze T, (2009) Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C. Georgian Med News. 175: 32-5.
24. Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C, (2010) Sustained virological response according to the type of early virological response in HCV and HCV/HIV. Ann Hepatol. 9(2): 150-5.
25. Chung HJ, Lee JW, Kim YS, Lee JI. (2013) Prediction of Sustained Virologic Response Based on Week 4 and Week 12 Response in Hepatitis C Virus Genotype 1 Patients Treated with Peginterferon and Ribavirin: Assessment in a Favorable IL28B Allele-Prevalent Area. Intervirology.[In press].
26. Bura M, Kowala-Piaskowska A, Adamek A, Bura A, Czajka A, et al. (2012) Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre. Postepy Hig Med Dosw [serial online]. 66: 339-47. Available: www.phmd.pl. Accessed 12 December 2012.
27. Vanegas NO, Román JL, Febles MH, Sánchez CG, Suárez JM, et al. (2011) Treatment of chronic hepatitis C virus infection. A study of best predictors for response. Rev Esp Quimioter. 24(4): 198-203.
28. Van den Eynde E, Tiraboschi JM, Tural C, Van den Eynde E, Tiraboschi JM, et al. (2010) Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients. AIDS. 24(7): 975-82.
29. Chung RT, Umbleja T, Chen JY, Umbleja T, Chen JY,et al; Actg A5178 Study Team (2012) Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials. 13(2): 70-82.
30. Coban S, Idilman R, Erden E, Tüzün A, (2011) Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology. 58(109): 1301-6.
31. Mauss S, Hueppe D, John C, Goelz J, Heyne R, et al. (2011) Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat. 18(4): e81-90.
32. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 364: 1195-206.
33. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, et al. (2013) Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 368(1): 45-53.
34. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 364: 2405-16.
35. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, et al. (2013) Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 368(1): 34-44.
36. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 54(4): 1433-44.
37. Yee HS, Chang MF, Pocha C, Lim J, Ross D, et al. (2012) Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 107(5): 669-689.
38. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, et al. (2012) UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 35(6): 647-62.
39. Seden K, Back D, Khoo S, (2010) New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. The Journal of antimicrobial chemotherapy 65(6): 1079-85.
40. Sulkowski M, S Pol, C Cooper, Fainboim J, Slim A,et al. Boceprevir+Pegylated Interferon+Ribavirin for the Treatment of HCV/HIV-co-infected Patients: End of Treatment (Week-48) Interim Results. [Abstract 47]. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2011; Seattle, WA.
41. Dieterich DT, Soriano V, Sherman KE, Girard PM, Rockstroh JK,et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis.[Abstract 46]. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2011; Seattle, WA.